logo
5 Monster Stocks to Hold for the Next 10 Years

5 Monster Stocks to Hold for the Next 10 Years

With the stock market settling in after a volatile period, now is a good time to start looking at some leading growth stocks that have strong potential over the next decade.
Here are five growth stocks across industries that investors can look to hold for the long term.
1. Taiwan Semiconductor Manufacturing
Taiwan Semiconductor Manufacturing (NYSE: TSM) is one of the most critical players in the artificial intelligence (AI) boom. As the world's leading contract chip manufacturer, TSMC manufactures the advanced semiconductors powering a range of products from AI infrastructure to smartphones and automotive tech.
Producing these chips isn't easy, as it requires leading-edge technology, precision manufacturing, and scale. Few companies in the world have the capabilities or the track record that TSMC does, and with competitors struggling, it has also garnered strong pricing power.
As such, the company has become the go-to partner for top chip designers, thanks to its leadership in advanced nodes and packaging. Advanced nodes refer to manufacturing processes that allow more transistors to be packed onto a chip, which in turn boosts performance and power efficiency.
Meanwhile, demand for high-performance computing, including AI chips, has exploded. With AI workloads growing, TSMC is expanding capacity alongside key customers to meet future demand.
Despite its pivotal role in the AI supply chain, TSMC's stock still looks reasonably valued. For long-term investors looking to benefit from the continued growth in AI infrastructure and semiconductors in general, TSMC is a great stock to hold.
2. Pinterest
Pinterest (NYSE: PINS) has undergone a quiet but powerful transformation under CEO Bill Ready. Over the past three years, the company has invested heavily in technology to turn its massive user base, which now sits at more than 570 million monthly active users worldwide, into a growth engine. Pinterest is no longer just an online vision board; it's become a shoppable platform with growing ad conversion capabilities.
One of the big drivers behind Pinterest's transformation has been its embrace of AI. The company built a multimodal model trained on both images and text to better understand what users are looking for. This powers personalized recommendations, while a visual search feature makes it easier for users to find and shop for products they see in pinned images. On the backend, meanwhile, its Performance+ platform is giving advertisers the tools to run better campaigns.
The results speak for themselves. Last quarter, Pinterest's revenue jumped 16%. Average revenue per user (ARPU) climbed across all regions, especially outside the U.S., where Pinterest is starting to better monetize users in emerging markets through the help of a partnership with Google.
Pinterest's stock still looks attractively valued, and the company is just scratching the surface of monetizing its user base. With AI-powered tools and a more shoppable platform, Pinterest has solid long-term investment potential.
3. Dutch Bros
Dutch Bros (NYSE: BROS) is shaping up to be one of the most compelling expansion stories in the restaurant space. With just over 1,000 locations across 18 states, the company believes it can more than double its footprint to 2,029 shops by 2029, and it sees the opportunity to eventually support 7,000 coffee shops nationwide.
Meanwhile, its small, drive-thru-focused shops are inexpensive to build, have attractive unit economics, and offer fast payback periods.
What makes the story even more attractive, though, is that Dutch Bros is only now starting to unlock other key growth levers. Mobile ordering, for example, is still early but gaining traction, accounting for only 11% of transactions last quarter. Mobile ordering also feeds into its loyalty program, allowing it to personalize its marketing and promotions.
The company is also leaning into food, testing hot items to drive breakfast sales at a few select locations. Food currently makes up less than 2% of sales, compared to nearly 20% at Starbucks, so there's real upside here. With more menu expansion and store openings on the way, Dutch Bros looks like a long-term winner.
4. Philip Morris International
Philip Morris International (NYSE: PM) is a growth stock in a defensive industry. While many tobacco companies are struggling with declining cigarette volumes in the U.S., Philip Morris doesn't have to worry about that because it doesn't sell cigarettes domestically. Instead, its growth is being driven by its smokeless portfolio, led by Zyn and Iqos, both of which have better unit economics than traditional cigarettes.
Zyn, its fast-growing nicotine pouch, has been its biggest growth driver, as evidenced by U.S. shipment volumes jumping 53% in Q1.
Meanwhile, Iqos, its premium heated tobacco product, continues to gain traction in Europe and Japan, with early success in new markets like Mexico City, Jakarta, and Seoul. In addition, after buying back its U.S. rights from Altria, the U.S. has the potential to be its next big growth driver. At the same time, its traditional cigarette business remains stable overseas, helped by strong pricing power and steady demand.
With strong pricing power, local manufacturing that limits tariff exposure, and growing demand for Zyn and Iqos, Philip Morris looks well positioned to keep delivering strong growth in the future.
5. Eli Lilly
Eli Lilly (NYSE: LLY) has emerged as a leader in the booming GLP-1 drug space, with surging demand continuing to drive strong revenue growth. Last quarter, its two key GLP-1 drugs -- Mounjaro and Zepbound -- generated a combined $6.1 billion in revenue, up sharply year over year. While Zepbound is officially approved by the Food and Drug Administration (FDA) for weight loss in obese adults or overweight adults with at least one weight-related condition, and Mounjaro is approved to help adults with type 2 diabetes, the reality is that the growth of these drugs is being driven by their being prescribed off-label for weight loss.
However, the drug that could be the biggest game changer for Lilly is still on its way. Orforglipron, its first oral GLP-1 drug candidate, recently demonstrated in a phase 3 trial that patients who took the drug lost considerable weight. As an oral medication, it is a much more convenient alternative to injectable GLP-1 drugs, making it especially appealing to patients who are wary of needles.
Orforglipron is also easier to manufacture and distribute than injectable drugs, as it doesn't require cold storage or injection pens. This should help Lilly avoid the supply constraints it saw with its injectable GLP-1 portfolio. With orforglipron looking like it has the potential to be the most potent oral GLP-1 weight loss drug on the market, Lilly is well positioned for continued future growth.
Should you invest $1,000 in Taiwan Semiconductor Manufacturing right now?
Before you buy stock in Taiwan Semiconductor Manufacturing, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Taiwan Semiconductor Manufacturing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!*
Now, it's worth noting Stock Advisor 's total average return is792% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 2, 2025
Geoffrey Seiler has positions in Philip Morris International and Pinterest. The Motley Fool has positions in and recommends Pinterest and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Dutch Bros and Philip Morris International. The Motley Fool has a disclosure policy.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Smart Healthcare Is Taking Over. Here's Where the Money's Headed

Cision Canada

time13 minutes ago

  • Cision Canada

Smart Healthcare Is Taking Over. Here's Where the Money's Headed

VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Inc. (NASDAQ: AMZN). McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030. Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. "We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally," said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. "We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare." Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July. While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix. In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vargas. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. Renovaro Inc. (NASDAQ: RENB) recently announced a major expansion to its intellectual property portfolio with a newly approved U.S. patent for its AI-powered drug discovery and diagnostics infrastructure. "This patent is a strategic milestone for Renovaro," said David Weinstein, CEO of Renovaro. "Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights." The patent protects methods that harmonize genomic, imaging, clinical, and health record data into a standardized framework for large-scale predictive analytics. These capabilities are built for distributed computing environments, aligning with the biopharma industry's move toward real-time, scalable analytics. The development enhances Renovaro's competitive positioning in data-driven therapeutics and clinical insight markets. Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL) recently showcased its leadership in AI-driven cancer research at the 2025 ASCO Annual Meeting, where Ruth Porat discussed Alphabet's evolving role in early diagnosis and treatment. "AI has greater potential than the internet, because it can augment human capabilities," wrote Ruth Porat, President & Chief Investment Officer of Alphabet and Google, quoting Vint Cerf. "It is a partner for all of you, for each of us." Porat highlighted Google's success with AlphaFold, which has accelerated cancer drug discovery by solving the decades-long problem of protein folding. She also noted the company's AI-assisted pathology tools that cut diagnostic time in half and improve detection of small metastases. From scalable diabetic retinopathy screening to generative AI for clinical workflows, she framed AI as a transformative force in healthcare delivery. Omada Health, Inc. (NASDAQ: OMDA) entered the public markets with a strong debut, raising $150 million and closing its first trading day 21% above IPO pricing. The company delivers AI-augmented virtual care for chronic conditions like diabetes, hypertension, and obesity, serving more than 679,000 active members. In May, prior to the IPO, Omada introduced Nutritional Intelligence, a new member experience powered by OmadaSpark—an AI agent that offers personalized, evidence-based nutrition coaching between clinical visits. As demand rises for GLP-1 medications, Omada is positioning its human-plus-AI model as essential to long-term metabolic health. "We believe there is a clear market need for real-time educational support backed by behavioral science to improve mindsets and behaviors toward food," said Wei-Li Shao, President at Omada Health. "To meet the needs of our customers and members, Omada fine tuned its approach to offer AI-powered tools trained with clinical input and expertise to work alongside human care teams in helping members drive improved health and economic outcomes." Inc. (NASDAQ: AMZN) continues to scale its digital health footprint via Amazon Web Services (AWS), which recently brought its HealthLake platform to the EU's Dublin Region. The move enables hospitals and insurers to unify siloed patient data using FHIR standards, while running AI-driven analytics and maintaining full data residency compliance. "I'm excited about AWS HealthLake launch in EU Region," said Ramon Postulart, CTO at Adapcare. " AWS HealthLake is a key AWS healthcare service helping us modernize interoperability across the 70+ care organizations and 60,000 health professionals we support in the Netherlands. By moving to this service, we're unlocking richer, standardized health data and leveraging the HealthLake fully managed capabilities to build smarter, AI-powered tools for care planning and coordination." HealthLake now serves as the engine behind personalized care tools in development across Ireland, the Netherlands, and Finland. AWS also hosted its Health Data & AI Day in Dublin to promote cross-border health data innovation and the European Health Data Space initiative. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

HCLTech Expands Partnership With The Standard to Accelerate AI-led Transformation and Deliver Digital-first Services at Scale
HCLTech Expands Partnership With The Standard to Accelerate AI-led Transformation and Deliver Digital-first Services at Scale

National Post

time24 minutes ago

  • National Post

HCLTech Expands Partnership With The Standard to Accelerate AI-led Transformation and Deliver Digital-first Services at Scale

Article content NEW YORK & NOIDA, India — HCLTech, a leading global technology company, announced an expansion of its partnership with Standard Insurance Company (The Standard), a leading provider of financial protection products and services for employers and individuals. Article content This expanded partnership with The Standard will deliver AI-driven infrastructure and application services to boost efficiency, support rapid growth and enhance customer experience. This collaboration will also accelerate The Standard's shift to an IT products and services-based operating model, enabling greater agility, customer value and progress toward the company's long-term digital transformation goals. Article content Article content HCLTech's GenAI-led service transformation platform, AI Force, digital engineering and cloud services will support The Standard's focus on exceptional customer service in the delivery of workplace benefits. This transformation will be further driven by a newly formed Joint Innovation Council and Digital Experience Office, reinforcing The Standard's commitment to innovation and delivering scalable, user-centric experiences. Article content 'The Standard's growth journey has accelerated in recent years through digital transformation and acquisitions, and HCLTech has proven to be the best partner to help us scale efficiently and seamlessly with its digital-first and customer-focused approach,' said Laxman Prakash, Chief Information Security Officer and Head of IT Infrastructure and Security Management Organization at The Standard. 'We look forward to the positive impact that this ongoing partnership will provide for our customers.' Article content 'We are excited about this extended partnership with The Standard, showcasing our deep commitment to the insurance sector,' said Anubhav Mehrotra, Senior Vice President, Head of Insurance, North America, at HCLTech. 'This collaboration underscores HCLTech's investment in AI-led capabilities and innovative talent, which have been pivotal in guiding The Standard through its digital transformation journey.' Article content is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit Article content The Standard is a family of companies dedicated to helping customers achieve financial well-being and peace of mind. In business since 1906, we are a leading provider of financial protection products and services for employers and individuals. Our products include group and individual disability insurance, group life and accidental death and dismemberment insurance, group dental and group vision insurance, absence management and paid family leave services, retirement plans products and services and annuities for employers and individuals. For more information about The Standard, visit and follow us on LinkedIn and Instagram. Article content Article content Article content Article content Contacts Article content For further details, please contact: Article content HCLTech Article content Meredith Bucaro, Americas Article content Article content meredith-bucaro@

Onfolio Holdings Inc. Launches Referral Partner Program to Accelerate Adoption of AI Visibility Services
Onfolio Holdings Inc. Launches Referral Partner Program to Accelerate Adoption of AI Visibility Services

Globe and Mail

time40 minutes ago

  • Globe and Mail

Onfolio Holdings Inc. Launches Referral Partner Program to Accelerate Adoption of AI Visibility Services

WILMINGTON, Del., June 10, 2025 (GLOBE NEWSWIRE) -- Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTCQB: ONFOP) ('Onfolio' or the 'Company') today announced the official launch of its Referral Partner Program to support the rapid growth of its Generative Engine Optimization (GEO) business. The program offers recurring income and long-term upside to professionals who refer clients to Pace Generative LLC, Onfolio's GEO subsidiary, which helps businesses gain visibility in AI-generated answers from tools like ChatGPT, Gemini, Claude, Grok, and Perplexity. For Onfolio, the program should help to capture the demand and scale revenues significantly faster. Generative Engine Optimization (GEO) is a fast-emerging discipline that positions businesses inside AI-generated responses, rather than simply helping them rank in traditional search engines. When prospective clients ask tools like ChatGPT, 'Who's the best cosmetic surgeon in Miami?' or 'Which estate planning firm in NYC is most reputable?', GEO helps to determine whether a business is mentioned in that real-time answer. 'With the way people now search for trusted services, the brands that show up in AI answers will win the next decade,' said Dominic Wells, CEO of Onfolio. 'Our mission is to ensure that great companies don't get left behind - and our referral partners will be essential to helping us scale that impact.' 'AI is now the first stop for answers,' Wells continued. 'If a company isn't cited, it's not just ranked lower, it's invisible. GEO addresses that. And our referral program allows trusted professionals to help their clients while building a new revenue stream for themselves.' For more information about Pace Generative LLC, visit For more information about our referral program, visit or contact Michael Carwile at partners@ About Onfolio Holdings Inc. Onfolio acquires, operates, and scales a diversified portfolio of digital companies. The Company focuses on businesses with strong cash flows, long-term growth potential, and experienced leadership—or those that can be effectively managed by Onfolio's in-house team. By targeting under-optimized businesses with untapped potential, Onfolio adds value through operational expertise, strategic guidance, and advanced technologies. For more information, visit www. Safe Harbor Statement The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continues," "estimates," "projects," "intends," and similar expressions. Examples of forward-looking statements include, among others, statements we make regarding expected operating results, such as revenue growth and earnings, and strategy for growth and financial results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing new customer offerings, changes in customer order patterns, changes in customer offering mix, continued success in technological advances and delivering technological innovations, delays due to issues with outsourced service providers, those events and factors described by us in Item 1.A "Risk Factors" in our most recent Form 10-K and Form 10-Q, other risks to which our Company is subject, and various other factors beyond the Company's control. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store